2OIQ image
Deposition Date 2007-01-11
Release Date 2007-03-20
Last Version Date 2023-08-30
Entry Detail
PDB ID:
2OIQ
Keywords:
Title:
Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.
Biological Source:
Source Organism:
Gallus gallus (Taxon ID: 9031)
Method Details:
Experimental Method:
Resolution:
2.07 Å
R-Value Free:
0.26
R-Value Work:
0.22
R-Value Observed:
0.23
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Proto-oncogene tyrosine-protein kinase Src
Gene (Uniprot):SRC
Chain IDs:A, B
Chain Length:286
Number of Molecules:2
Biological Source:Gallus gallus
Primary Citation
c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty.
Structure 15 299 311 (2007)
PMID: 17355866 DOI: 10.1016/j.str.2007.01.015

Abstact

The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor. Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src. The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl*imatinib and c-Kit*imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases. Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodynamic penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure. Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.

Legend

Protein

Chemical

Disease

Primary Citation of related structures